fbpx

QQQ
-0.59
373.57
-0.16%
BTC/USD
-1424.23
42165.30
-3.27%
DIA
-0.02
347.58
-0.01%
SPY
+ 0.29
442.90
+ 0.06%
TLT
-1.09
149.45
-0.73%
GLD
+ 0.40
163.12
+ 0.24%

Can Ketamine Be Used To Treat Gambling Addiction? Awakn Life Sciences Wants To Find Out

August 24, 2021 5:14 pm
Share to Linkedin Share to Twitter Share to Facebook Share to Print License More
Can Ketamine Be Used To Treat Gambling Addiction? Awakn Life Sciences Wants To Find Out

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:AWKNF), a biotech company developing psychedelic medicines for addiction, has received approval to launch a human study looking into the effects of ketamine in gambling addiction.

The early-stage study will analyze if ketamine administration can modify reward memories associated with gambling, and if successful, will serve as the basis for possible clinical trials using the same method in improving gambling addiction.

While Awakn has begun recruiting human participants, this study is not a clinical trial, explained Prof. Celia Morgan, Awakn’s head of ketamine-assisted psychotherapy, in an interview with Benzinga.

“It’s a mechanistic study, where we’re looking at modulating memory,” she added. “We’re not looking at clinical outcomes, so we’re not looking at changes in gambling severity as an outcome of this. We’re simply looking to see how strongly people react to gambling queues.”

Treating Addiction By Modifying Memories With Ketamine

Through this study, the research team is trying to understand if, by blocking the body’s NMDA receptors, ketamine can block the reconsolidation of memories associated with gambling behaviour.

Memory reconsolidation is a process by which previously consolidated memories are recalled and actively consolidated. This process serves to maintain, strengthen and modify memories stored in long-term memory. By tapping into this process, ketamine could modify fixed memories that trigger compulsive behaviour.

“Recent scientific evidence has shown that when you reactivate a memory, this one is not only able to be updated but also weakened and potentially destroyed if you block a biological process known as reconsolidation, which agents like ketamine can do,” Morgan said.

The team will try out a new paradigm in which they will ask gamblers to reactivate a gambling memory and then administer ketamine within that window.

If the strong memories that lead to compulsive behaviour can be weakened, ketamine could have a very valuable therapeutic effect in the treatment of addiction and behavioural disorders, by breaking the reward cycle associated with initial memories.

Photo: Michał Parzuchowski on Unsplash

For the latest in financial news, exclusive stories, memes follow Benzinga on Twitter, Facebook & Instagram. For the best interviews, stock market talk & videos, subscribe to Benzinga Podcasts and our YouTube channel.


Related Articles

Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial

Psyched: First Active Psychedelics ETF Hits NYSE, Compass Dives Into Novel Molecules, Atai Subsidiary Launches Phase 2a Trial

AdvisorShares Launches First NYSE-listed Actively-managed Psychedelics ETF On Thursday, AdvisorShares launched the country’s first actively managed ETF covering the psychedelics sector. read more
Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold

Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold

Contents read more
Psyched: Atai Launches 'Salvia Divinorum' Subsidiary, Mindset, Psilera and Wesana's Preclinical Trials, Origin Raises $5M

Psyched: Atai Launches 'Salvia Divinorum' Subsidiary, Mindset, Psilera and Wesana's Preclinical Trials, Origin Raises $5M

Atai Life Sciences Launches New Salvia Divinorum Subsidiary Atai Life Sciences (NASDAQ: ATAI) announced the launch of a new subsidiary that will research Salvinorin A, the active compound in salvia divinorum, a hallucinogenic herb native to Central America. read more
Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected

Psyched: Field Trip Uplists To Nasdaq, MindMed To Study DMT, Atai Launches New Subsidiary, AOC's Psychedelics Amendment Rejected

Last week in Psychedelics: read more